



<http://europeanshocksociety.org/>  
<https://www.facebook.com/europeanshock/>

## Contents

Message from the European Shock Society President .....	2
Message from the General Secretary.....	3
The Treasurer’s Corner.....	4
Our ESS Brother Gone... Commemorating Tomasz Skirecki .....	5
Updates on the 2025 ESS Congress .....	7
Introducing the 2025 ESS Keynote Speaker: Fabienne Venet.....	9
Introducing the 2025 ESS Keynote Speaker: Tom van der Poll.....	10
ESS 2025 Summer School: From Injury Site to Bench to Bedside.....	11
ESS 2025 Congress Workshops: Targeting Trauma, Shock and Sepsis Care and Research – Practical Skills.....	13
ESS 2025 Congress Abstracts to be Published in <i>Shock</i> Journal Supplement.....	15
The Immunosep Project: Update.....	16
Spotlighting the Most Important Publication You Read in 2024/25 – Part 1.....	18
Spotlighting the Most Important Publication You Read in 2024/25 – Part 2.....	19
New S3 Guideline on Intensive Care Medicine After Polytrauma Published .....	22
New European White Book on Polytrauma Management across Europe by the European Society for Trauma and Emergency Surgery (ESTES) published .....	23
The Global Sepsis Alliance Amplifies Advocacy and Partnership Efforts .....	24
Welcome New ESS Members .....	26
Upcoming Events.....	27
Invitation to Publish in <i>Shock</i> ® .....	28
"A new/old course for the <i>Shock</i> journal" or "A new vision for Shock" .....	28
The Executive Committee of ESS .....	29
ESS Membership .....	33
How to Become an ESS Member? .....	33
Last Words About the ESS Newsletter .....	34

## Message from the European Shock Society President



**Dear ESS members, colleagues, and friends,**

As I continue in my role as President of the European Shock Society, I am filled with deep gratitude and renewed determination to carry forward the legacy of our Society—built over decades by passionate and visionary individuals. Today, ESS stands as a strong, inclusive, and forward-looking community thanks to the dedication of those who paved the way.

In 2023, we marked a milestone: the 40th anniversary of ESS. This celebration honored four decades of scientific excellence, collaboration, and community. It reminded us not only of how far we've come but of the enduring bonds that unite us across generations and disciplines.

Life, however, brings moments of both celebration and profound loss. It is with deep sadness that we acknowledge the passing of Tomasz Skirecki, a cherished friend and esteemed colleague. Tomasz was a passionate clinician and a brilliant researcher in sepsis immunology. More than that, he was a warm, generous spirit—whether in the hospital, the lecture hall, or at informal gatherings. His sudden departure leaves a deep void, but his legacy will continue to inspire us in our scientific and human endeavors.

As we reflect on our community, we remain mindful of the broader world—a world marked by both unity and division, progress and uncertainty. From the ongoing wars in Ukraine and Gaza to global unrest, we are all affected by the forces shaping our societies. Yet, in the ESS, I find a source of hope. We remain committed to open dialogue, scientific rigor, human solidarity, and mutual respect—across borders, disciplines, and beliefs.

I'm excited to announce the **21st biennial Congress of the ESS**, taking place from **September 18–21, 2025**, in the beautiful city of **Dubrovnik, Croatia**. It is the first ESS Congress ever hosted in Croatia, my country of origin. This event will carry forward our tradition of excellence while opening new chapters in scientific exchange, collaboration, and inclusivity. Preparations are well underway, and we are building an event that reflects both our rich tradition and our bold future. I warmly invite you to be part of this Congress—not only by attending, but by helping shape it. Whether you're submitting research, proposing a talk, or mentoring scientists, your contribution matters. Let's make this a shared success. As we enter our fifth decade, I believe the ESS is more relevant than ever. Let's harness the diversity, energy, and talent within our membership to push boundaries—in science, in mentoring, and in outreach. This is our moment to move forward, together.

In closing, I'd like to share a quote that continues to inspire me:

**“The only limit to our realization of tomorrow will be our doubts of today.”**

—Franklin D. Roosevelt


Let us step boldly into the future—with confidence, curiosity, and collaboration.

Warm regards,

**Your Borja Relja**

President of the European Shock Society

## Message from the General Secretary



Dear colleagues, dear members and friends of ESS,

Above all, I would like to express my sincere gratitude to our members for their unwavering loyalty and commitment to the ESS.

I am pleased to report that the ESS membership has grown since the 2023 Congress (we gained 6 new members immediately after the last Congress and recently 7 new members joined us)!

The Board held an online meeting in November 2024, where, among others, our President Borna presented the programme and financial plan for the Dubrovnik Congress. There was also a discussion about the status of my further work on the ESS website.

We have made improvements to the online membership registration system on the [ESS website](#). After registering in the [ESS membership database](#), new registrants will receive a quick notification of the second step, the payment of the membership fee. In addition, a new development is the possibility to use the website to send automatic notifications shortly before and after the expiration of the membership fee. ***We therefore ask you, our dear friends, not to take these reminders as an insult but to urgently take advantage of the opportunity to renew your membership.*** Thank you very much! We will endeavour to provide you with confirmation of the payment of your membership fee by e-mail as soon as possible, but you can also check your membership status and the [date of your last membership fee payment](#) via the website. On our website we continue to share information on the forthcoming congress of the ESS and other societies. ESS also manages the website for the International Federation of Shock Societies ([IFSS](#)). Here is also an option to pay by [credit card payment option](#) of the ESS membership fee.



**Global  
Sepsis  
Alliance**

*details about the activities of GSA in the newsletter*). Evangelos Giamarellos-Bourboulis (our former President) is the chair of the [European Sepsis Alliance](#).

The ESS has continued to cooperate with other associations. ESS has been a member of the [Global Sepsis Alliance](#) (GSA) since 2013 and supports its activities by transmitting the GSA initiative to ESS members and presenting relevant content on the ESS website (you can *find more*



**European  
Sepsis  
Alliance**

Marcus-Huber Lang, our former President and current member of the ESS Board, has become President-Elect of IFSS. Marc Maegele (our President-Elect) still serves as a representative of ESS in the ABC Trauma initiative and a treasurer of IFSS. ESS also supports ESTES and ESOT.

**Final words:** We warmly welcome our new members, but it should be noted that the society still greatly values its loyal “old” members. Everyone’s contribution is important - not only in organizing congresses or serving as section chairs, but also in developing the content of the ESS newsletter. We count on you!

Your secretary  
Andrea Szabó

## The Treasurer's Corner



Dear colleagues, members, students, and friends of the ESS,

Financial stability is of utmost importance to our society. It provides a solid foundation for all our activities, both now and in the future. It is a great honor for me to have been appointed treasurer at our last amazing conference in Vienna. If you and the other members and friends continue to support us financially and remain active members of our society, we will be able to continue our work and hopefully be even more financially stable in the years to come. The aim of the society is to train and support physicians and scientists in the fields of shock, trauma, and sepsis, and to provide platforms for scientific exchange between young scientists, researchers, and physicians. We wish to continue to attract younger members and integrate them in the best possible way into our society in order to be excellently positioned for the future.

The ESS collects membership fees separately from the registration fee for the biennial congress. If you have not yet paid your ESS membership fee for 2024/25, please do so now. The membership fee is currently €100 for regular members and €50 for student members, each for a period of two years. To pay your membership simply follow the instructions from the Chapter ESS Membership from this newsletter. The ESS depends on your membership for its existence.

I would like to express my sincere thanks to all ESS members and friends who have supported our society in recent years and continue to do so.

Your ESS Treasurer

[Sina Coldewey](#)

## Our ESS Brother Gone... Commemorating Tomasz Skirecki



Most of you are already aware of Tomek's passing at a young age of 37 as we communicated the somber news *via* email and website. We wish to say farewell to Tomek once again via our Newsletter.

Tomek was a Polish MD, PhD, anesthesiologist and scientist, professor in the Medical Center of Postgraduate Education (MCPE) in Warsaw, Poland, and Head of the Department of Translational Immunology and Experimental Intensive Care at MCPE ([www.cmkp.edu.pl](http://www.cmkp.edu.pl)). He simultaneously worked as a clinician at the National Medical Institute Hospital ([www.gov.pl/web/cskmswia-en](http://www.gov.pl/web/cskmswia-en)) in Warsaw. Since several years, Tomek was an active member of our society—he attended his first ESS congress in 2013 in Vienna and continued to be embedded in our ESS family. You might not know that, but he was the youngest appointed and then elected councilor of the European Shock Society.

Tomek was a brilliant doctor-

scientist, and this statement is merited by several accomplishments. He was the recipient of several national and international research grants. In 2017, he received the Austrian Günther Schlag Award recognizing Outstanding Early Career Scientists in Translational Research, and in 2020, Tomek was honored as an Outstanding Young Scientist by the Polish Ministry of Science and Higher Education. In response to the COVID-19 pandemic, his research project was awarded the prestigious Polpharma Scientific Foundation grant.



(Tomek receiving Günther Schlag Award from Heinz Redl, ESS Past President)

Tomek's research focused on the pathophysiology of sepsis, whether at the bedside or in pre-clinical porcine or murine sepsis models, including humanized mice. Among his many contributions, his seminal research deciphering the contribution of inflammasome in COVID-19 and in *Acinetobacter baumannii*-induced pneumonia are especially interesting. Tomek designed experimental models illustrating the compartmentalization of the immune response during sepsis, particularly regarding the lung cells and bone marrow derived myeloid and multipotent progenitor cells. He demonstrated that the bone marrow is the primary site of CD4+ memory T cell homing and proliferation after sepsis-induced lymphopenia and identified IL-7 as the major inducer of proliferation of these memory CD4+ T cells.

Personally, Tomek was simply a marvelous human being, a warm, emphatic, caring person with a great sense of humor. He was fan of Tina Turner and David Bowie, in love with Italian architecture, a true connoisseur of good food with considerable skills as an amateur chef. Many of you had a chance to occasionally chat with him on the subjects of research, art, food or life over a glass of fine red wine.

Marcin and the ESS Executive Committee

**We, the ESS council, do not want His passing to go unnoticed. Please keep Tomek in your heart and mind for the years to come.**



Your ESS Family

## Updates on the 2025 ESS Congress



Dear ESS Congress participants *in spe!*

We're thrilled to share that preparations for the 21st Congress of the ESS are in full swing—and this one is going to be truly special. For the first time in the Society's 42-year history, the congress is heading to Croatia, and we couldn't be more excited to welcome you to the historic coastal city of Dubrovnik. The venue? Only one of the most iconic cities in the Mediterranean! With its UNESCO-protected old town, monumental stone walls, and stunning views over the Adriatic, Dubrovnik is one of the most inspiring and picturesque places in Europe. Imagine vibrant scientific discussions—and just as importantly, reconnecting with colleagues and friends surrounded by medieval stone walls and views of the turquoise Adriatic Sea—yes, that's exactly what we're planning.

We've put together a rich and diverse scientific program, shaped by a collaborative international committee and the ESS Executive Council. Spread across three full congress days, the agenda includes scientific sessions, hands-on workshops, poster presentations, keynotes, and of course—ample opportunities to network, reconnect, and celebrate our collective progress. In that spirit, we are fortunate to welcome two outstanding keynote speakers, Fabienne Venet and Tom van der Poll, who will be joining us in Dubrovnik and staying throughout the congress. You can find their introductory profiles in the article below. We're equally excited to host our “invited” speakers, all of whom have graciously agreed to join us at their own expense—a testament to the enduring spirit of collegiality and the scientific value ESS congresses offer. If you're one of them: thank you for your generosity and dedication!

Here are some ESS2025 Congress highlights:

- **Historic First in Croatia**—hosted in one of Europe's most breathtaking coastal cities.
- **High-Impact Scientific Sessions**—Covering the latest in trauma, sepsis, organ dysfunction, critical care innovation, and bioengineering.
- **World-Class Keynote Speakers**—Featuring thought leaders and pioneers in our field.
- **Distinguished International Speakers**—Including leaders from both academia and clinical practice.
- **Hands-On Expert Workshops**—from clinical practice for academia and *vice versa*.
- **ESS Shock Summer School**—Training powered by DFG FOR5417: *From Injury Site to Bench to Bedside*.
- **European New Investigator Award Competition**—Showcasing the brightest upcoming talent in the field.
- **Interactive Poster Sessions & Awards**—Featuring dedicated poster tours, live discussions, and thematic awards.
- **Global Collaborations in Action**—Joint Events with our sister Shock Societies.
- **Support for Young Investigators**—Including travel grants, student sessions, mentorship, and award opportunities.
- **Iconic Venues & Cultural Events**—In UNESCO-listed Dubrovnik Old Town, included for all registered participants.

Dubrovnik will be the stage for an unforgettable program. Expect beautiful venues, good music, even better food, and a few magical sunsets over the Adriatic.

[Back to Contents](#)

Massive thanks go out to our local and international organizing teams, the ESS Council members, and everyone involved in putting this event together—especially those behind the scenes handling the logistics and technicalities with precision and passion.

So, mark your calendars:

*Dubrovnik, Croatia – September 18–21, 2025.*

**ESS 2025 information:** <https://europeanshockociety.org/Welcom---21st-Congress-of-the-European-Shock-Society-September-18-21-2025>

**ESS 2025 registration:** <https://prijava.dubrovniksun.hr/ess-2025/>



THU   18 September	FRI   19 September	SAT   20 September
<p>10:00 - 15:00 <b>Summer School</b> by the DFG FOR5417 From Injury Site to Bench to Bedside Hall 3</p> <p>13:00 - 15:00 <b>ESS Council Meeting</b> Invitation Only Hall 1</p> <p>15:00 - 16:30 <b>Session 1</b> Precision Phenotyping for Personalized Medicine in Critical Care Hall 3</p> <p>16:30 - 18:00 <b>Session 2 by the CRC1149</b> 'Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma' Hall 3</p> <p>18:00 - 18:10 <b>Welcome and Opening</b> Presidential Message Hall 3</p> <p>18:10 - 18:55 <b>Keynote – Fabienne Venet</b> Hall 1</p> <p>19:00 - 21:30 <b>Reception and Get Together</b> Pool Area</p>	<p>08:00 - 09:45 <b>Session 3</b> Multidimensional Crosstalk - Integrative Approaches to Cell Type, DAMPs, Omics, and Organ Specificity in Critical Illness Hall 1</p> <p>09:45 - 10:15 <b>Coffee Break</b> Floor Area</p> <p>10:15 - 11:45 <b>Session 4</b> Meet the Game Changers - Revolutionary Solutions and Achievements in Trauma and Sepsis Hall 1</p> <p>11:45 - 12:30 <b>Keynote – Tom van der Poll</b> Hall 1</p> <p>12:30 - 13:30 <b>Lunch Break</b> Restaurant</p> <p>13:30 - 15:15 <b>Session 5</b> Sepsis - Emerging Clinical Perspectives and Research Innovations Hall 1</p> <p>15:15 - 15:30 <b>Coffee Break</b> Floor Area</p> <p>15:30 - 17:00 <b>Session 6</b> Guest Societies: US Shock Society and TBA Hall 1</p> <p>17:00 - 18:30 <b>Poster Session 1</b> Risk Factors and Comorbidities in Trauma and Sepsis Hall 2</p> <p>17:00 - 18:30 <b>Poster Session 2</b> Polytrauma and Shock Hall 3</p> <p>19:30 - 22:00 <b>Dinner and Informal Discussions</b> Konoba Dubrava</p> <p><b>Registration Desk - Hotel Kompas</b> Thu – All day starting at 08:00 Fri and Sat – All day starting at 08:00 Floor Area</p>	<p>08:00 - 09:45 <b>Session 7</b> Innovations in Future Directions Hall 1</p> <p>09:45 - 10:15 <b>Coffee Break</b> Floor Area</p> <p>10:15 - 11:30 <b>Session 8</b> Organized by Young ESS Members - AJIC Hall 1</p> <p>11:30 - 13:00 <b>Session 9</b> European New Investigator Award Competition Hall 1</p> <p>13:00 - 14:00 <b>Lunch Break</b> Restaurant</p> <p>14:00 - 15:30 <b>Session 10</b> Advanced Approaches to Polytrauma and Shock - From Pathogenesis to Therapy Hall 1</p> <p>15:30 - 15:45 <b>Coffee Break</b> Floor Area</p> <p>15:45 - 16:30 <b>General Assembly ESS</b> Open to All Hall 1</p> <p>17:00 - 19:00 <b>"Boarding"</b> Old Town</p> <p>19:00 - 23:00 <b>Dinner and Awards</b> Karaka</p> <p>09:45 - 11:30 <b>Poster Session 3</b> Sepsis Hall 2</p> <p>14:00 - 15:45 <b>Poster Session 4</b> Divers Hall 2</p>

**Abstract submission deadline: 31.05.2025**

Come for the science, stay for the scenery—and let's make the 21st ESS Congress a landmark in more ways than one.

See you by the sea!

Warm regards,

Borna Relja

ESS President and ESS 2025 Congress Organizer

[Back to Contents](#)

## Introducing the 2025 ESS Keynote Speaker: Fabienne Venet



We are truly honored to announce that this year's keynote address on immunomonitoring aspects to advancing patient's stratification in clinical trials will be delivered by Professor Fabienne Venet, a leading voice in immunology and a dedicated clinical researcher from Lyon, France. Professor Venet holds a Doctor of Pharmacy from the Faculty of Medicine in Lyon and earned her PhD in Immunology from Université Claude Bernard Lyon. Her doctoral thesis, titled “Sepsis-induced immune alterations: study of T lymphocyte reprogramming,” laid the foundation for what has become a prolific and impactful career at the interface of basic science and clinical application. Following her PhD, Professor Venet further enriched her expertise during a postdoctoral fellowship in the lab of Professor Alfred Ayala at the Shock and Trauma Research Lab, Lifespan–Rhode Island Hospital, and the Alpert Medical School at Brown University in Providence, USA.

Currently affiliated with Université Claude Bernard Lyon and Hospices Civils de Lyon, Professor Venet has dedicated her career to unraveling the intricate immunological mechanisms that govern the body's response to sepsis. Her research has significantly advanced our knowledge of sepsis-induced immunosuppression, particularly in identifying biomarkers that predict patient outcomes. Notably, her studies on monocyte human leukocyte antigen-DR (HLA-DR) expression provided valuable insights into the prognostic assessment in sepsis.

Her influential 2018 review in *Nature Reviews Nephrology* offered a comprehensive look at the mechanisms of sepsis-induced immunosuppression and discussed potential therapeutic strategies aimed at stimulating immune functions in affected patients. Her recent *Nature Communications* paper broke new ground by identifying the regulatory PD-L1<sup>+</sup> plasma cells as suppressors of T cell responses during sepsis in both mice and humans —highlighting a potential new target for restoring immune function in septic patients.

With over 11,600 citations and a research portfolio that seamlessly bridges experimental immunology with translational and clinical medicine, Professor Venet is a global leader in advancing personalized, immune-guided therapies for critically ill patients. Her work continues to inspire the design of immune-monitoring strategies and clinical trials for immunostimulatory therapies in sepsis.

We eagerly anticipate Professor Venet's keynote address and the valuable insights she will share with us at this year's conference.

Christian Bergmann (ESS Councillor Appointed by the President)

## Introducing the 2025 ESS Keynote Speaker: Tom van der Poll



Professor Tom van der Poll is a renowned physician-scientist with expertise in internal medicine and infectious diseases. He currently serves as Chair of the Department of Medicine at Amsterdam University Medical Centers (Amsterdam UMC), affiliated with the University of Amsterdam. He obtained his medical degree and completed his PhD at the Academic Medical Center in Amsterdam, where his doctoral research on tumor necrosis factor (TNF) led to groundbreaking publications in the *New England Journal of Medicine*. He further refined his expertise during a postdoctoral fellowship at Cornell University Medical College in New York.

His research focuses on the immunopathology and immunotherapy of pneumonia and sepsis, with particular emphasis on the innate immune response, especially pattern recognition receptors, and the regulation of the pro-coagulant response. His work seeks to uncover the mechanisms by which these immune and coagulation pathways are activated, connected, and controlled during infection. His translational approach bridges clinical observation in patients with mechanistic studies in healthy volunteers and genetically modified mouse models. Professor van der Poll has made a lasting impact on sepsis research, notably through the MARS project, which has yielded transformative publications in *JAMA*, *The Lancet Respiratory Medicine*, *Nature Immunology*, *Intensive Care Medicine*, and *the American Journal of Respiratory and Critical Care Medicine*.

Internationally, Professor van der Poll has significantly shaped the field's direction as a former Chair of the International Sepsis Forum and a contributor to the 2016 revision of the international sepsis definitions published in *JAMA*. He has been a driving force in several major European research consortia focused on pneumonia, peritonitis, and sepsis, including COMBACTE-CARE, COMBACTE-MAGNET, and IMMUNOSEP, initiatives aimed at biomarker discovery and validation that have created important new opportunities for translational science.

With over 1,000 publications, his work is widely cited and continues to influence the fields of infectious diseases, immunology, and critical care medicine. Through his leadership at Amsterdam UMC and sustained contributions to research, Professor van der Poll remains at the forefront of efforts to advance the understanding and treatment of life-threatening infections, bridging the gap between bench and bedside.

Brendon P. Scicluna (ESS Councillor and Council Member)

## ESS 2025 Summer School: From Injury Site to Bench to Bedside

Organized by Clinician Scientists and ESS Members:



Birte Weber  
(ESS Member)



Aileen Ritter



Christian Bergmann  
(ESS Member)



Nils Becker  
(ESS Member)

This year's ESS Summer School, funded and organized by the DFG-Research Group FOR5417 (*Translational Polytrauma Research to Provide Diagnostic and Therapeutic Tools for Improving Outcomes*), offers a unique opportunity to explore the clinical aspects of critical care and emergency medicine in severely injured patients, integrated with the latest advances in basic research. Key topics include inflammation, immune-dysregulation, surgical therapy, and post-traumatic complications.

Our diverse program is designed to engage early-career basic scientists interested in the clinical context of their work, young healthcare professionals, and highly motivated students. This interdisciplinary Summer School welcomes participants from all educational backgrounds and research fields.

The four interactive sessions will cover fundamental principles of acute care management of severely injured patients, with a strong emphasis on hands-on learning. Each session will highlight the vital connection between clinical practice with its treatment concepts and current research, offering participants an excellent insight into the clinical background of emerging trends and innovations in trauma and sepsis.

### ESS 2025 Summer School:

**Session 1:** Prehospital and Acute In-Hospital Medical Care

**Session 2:** Emergency Surgery Concepts and Early Inflammatory Response

**Session 3:** Intensive Care, Post-Traumatic Complications, and Immune Dysregulation

**Session 4:** Current Advances in Trauma Research – From Bedside to Bench and Back

All interactive sessions will be led by clinical scientists involved in the DFG-Research Group FOR5417 with expertise in trauma surgery and trauma-focused research.

### Details:

- **Date:** 18th September 2025
- **Time:** Starting at 10:00 a.m.
- **Location:** Conference site of the 2025 ESS Congress
- **Cost:** Free for participants registered for the ESS 2025 Congress
- **Catering:** Coffee breaks and lunch will be provided

[Back to Contents](#)

- **Capacity:** Limited to 20 participants (“first come, first served”; waiting list available)
- **Travel Awards by the DFG FOR5417:** €250 granted to Summer School participants.
- **DFG FOR5417 Awards:** Two additional €250 Awards granted to best talks by the Summer School participants at the ESS 2025.

**Important:** Pre-registration is required. To apply, please send an email to: [summerschool@ess2025.org](mailto:summerschool@ess2025.org)

Take advantage of this excellent opportunity to expand your knowledge, enhance your skills, and network with peers across disciplines!

Birte, Aileen, Christian and Nils

## ESS 2025 Congress Workshops: Targeting Trauma, Shock and Sepsis Care and Research – Practical Skills


We're thrilled to offer three engaging and hands-on workshops at this year's conference. Whether you're a clinician, researcher, or student, these sessions offer valuable insights into cutting-edge topics in trauma and critical care.

### Workshop 1: Point-of-Care Viscoelastic Testing in Hemorrhagic Shock

Learn how viscoelastic testing is transforming the management of acute bleeding in trauma care.

organized by Marc Maegele (President-Elect of the ESS)

### Workshop 2: From Data to Discovery: Master Modern Flow Analysis with Cytolution



Learn how to master flow data analysis with ease. Integrate Automated Transformation, Batch Effect Correction, Data Cleaning, Labeling, without coding experience. Simplify gating with automated Population Annotation tools, identify significant populations effortlessly with advanced algorithms, and uncover hidden patterns through Clustering and Dimensionality Reduction (t-SNE, UMAP, and Cyto Model). Whether you're a beginner or an expert, this workshop is tailored to provide valuable insights for everyone.

**Award “Young Innovator in Flow Cytometry” funded by Cytolytics: €500 to a workshop participant**

Funded by Cytolytics (<https://cytolytics.de/>) and organized by Serina Pinar and Can Pinar

### Workshop 3: Modelling in Trauma and Sepsis hosted by the Network Trauma Research (NTF)

To deepen our understanding of injury, shock, and sepsis, experimental research relies on a range of models, primarily *in vivo* rodent models, to simulate and investigate these complex conditions. However, especially for early career scientists who are new to the field, navigating these experimental models can be challenging.

Our workshop organized by the NTF of the German Society for Orthopedic and Trauma Surgery (DGOU) aims to bridge that gap. It will provide a comprehensive introduction to most commonly used experimental models, offering valuable insights into their methodologies, applications, and read-out techniques, while also exploring their advantages and limitations: Burn Shock, Cecal Ligation and Puncture, Acute Respiratory Distress Syndrome, Polytrauma Modelling, Traumatic Brain Injury, and *In vitro* Modelling of Trauma and Shock.

Organized **by young scientists for young scientists**, the workshop features hands-on experts who not only have a strong grasp of the theoretical aspects but also use these models in their


[Back to Contents](#)

daily research. It aims to equip participants with a deep understanding of these models, empowering them to make well-informed decisions in their own research, all while providing a vibrant environment to ask questions, share experiences, and dive into engaging discussions.

Organized by ESS Post Docs:



Jasmin M. Bülow  
(ESS Member)



Katrin Bundkirchen



Helen Rinderknecht  
(ESS Member)

Join Us On-Site!

### Important Details for All Workshops:

- **Cost:** Free for participants registered for the ESS 2025 Congress
- **Catering:** Coffee breaks and lunch will be provided
- **Capacity:** Each workshop is limited to ~15 participants
- **Participation\*:** “first come, first served”; waiting list available
- **Awards**

\*The capacity is limited (“first come, first served”; waiting list available), so make sure to register as soon as possible. Pre-registration is possible. To pre-register, please send an email indicating Workshop 1, 2 or 3 to: [info@bornarelja.com](mailto:info@bornarelja.com)

In case of open spots, registration for all workshops will be available at the conference venue.

Take advantage of this excellent opportunity to expand your knowledge, enhance your skills, and network with peers across disciplines!

We look forward to your participation and to advancing trauma science together.

## ESS 2025 Congress Abstracts to be Published in *Shock* Journal Supplement

### Important Announcement:

We are pleased to inform all participants that all accepted abstracts, including those from invited talks that will be captured as abstracts, will be published as a supplement to the journal *Shock*, under the meeting's official ESS supplement.

This publication provides a valuable opportunity for your work to be indexed and disseminated through a widely recognized scientific platform, reaching a global audience in the field of shock, trauma, and critical care research.

We encourage all contributors to ensure the accuracy and completeness of their abstract submissions, as they will appear in the official publication.

### Important for Invited Speakers:

All talks can be submitted as abstract text, not exceeding 300 words.

For those of you giving invited talks and looking to get a head start for abstract publication:

You can find the abstract submission form under: <https://europeanshocksociety.org/Welcome--21st-Congress-of-the-European-Shock-Society-September-18-21-2025>

Only invited speakers: Please send your abstracts directly to the Congress President via the email address ([info@bornarelja.com](mailto:info@bornarelja.com)) you've been using for correspondence regarding your invited talk.

Stay tuned for further updates on timelines and access details for the ESS supplement.



Borna Relja  
President ESS

## The Immunosep Project: Update



As sepsis is the epitome of complexity in terms of immune response/immune dysregulation, a therapeutic approach including immunotherapy is of paramount importance. Patient heterogeneity represents a major challenge. Sepsis classification into distinct endotypes offers a promising strategy of precision immunotherapy. So far, two distinct endotypes have been identified:

- **MALS** (macrophage activation-like syndrome), characterized by hyperinflammation and high ferritin levels, and
- **Immunoparalysis**, characterized by low interferon gamma levels and impaired antigen presentation capacity.

*Picture: Immunosep Kickoff meeting, Radboud, February 2020*

The **Immunosep** project brought together fourteen partners across nine countries aiming to conduct the first trial of precision immunotherapy globally.

The study was designed as a double-blind, double-dummy randomized clinical trial and patients were randomly assigned to one of two groups: **immunotherapy** or **standard of care**. Patients assigned at the immunotherapy arm were further classified into two groups based on relevant biomarkers: hyperinflammation (identified by elevated ferritin levels) and immunoparalysis (identified by decreased monocyte HLA-DR expression). Administration of the study drug was the outmost challenge. All patients received one intravenous and one subcutaneous intervention. Patients in the active arm with MALS were treated with intravenous anakinra and subcutaneous placebo; those in the active arm with immunoparalysis received intravenous placebo and subcutaneous recombinant human interferon-gamma; those in the placebo arm received both placebo treatments.

The trial was conducted in 34 sites in Europe (Germany, Greece, Italy, The Netherlands, Romania, Switzerland).

Our journey started back in 2020, and, despite the COVID-19 pandemic breaking out just one month after the kick-off meeting, we successfully enrolled the last patient in January of 2024. Overall, 672 patients were screened and 281 were enrolled.

The study was sponsored by Hellenic Institute for the Study of Sepsis (HISS; <https://sepsis.gr/>). HISS supervision included clinical trial protocol drafting, finalization and submission in six

[Back to Contents](#)

European countries; and running and completing the trial in these six countries. In total, more than 240 monitoring visits were performed and more than 1300 packages were delivered to central lab with more than 7000 samples for handling and processing.

I truly believe this achievement would not have been feasible without the passion, dedication and tireless efforts of all involved partners. It would not be an exaggeration to say that all investigators embraced this clinical trial as a personal goal, overcoming all possible obstacles on top of everyday clinical and research burden. Still, there are still many more challenges to come like multi-omics characterization of sepsis, systems biology and theragnostic integration.

As the moment to announce the results approaches, we can only hope that we are finally near to a game-changing discovery. Finally, we must underscore that this endeavor could not have been accomplished without the 281 patients and their families that honored us with their trust and willingness to participate in the study and without having on board Professor Netea, who is responsible for managing and coordinating this whole magic scientific project.

Antigoni Kotsaki  
(Auditor of the ESS and ESS Member)

## Spotlighting the Most Important Publication You Read in 2024/25 – Part 1

Contributions by:



Martin Sebastian Winkler  
(ESS Member)



Jean-Marc Cavaillon  
(Past President and ESS Member)

doi: [10.1001/jama.2024.26458](https://doi.org/10.1001/jama.2024.26458)

Dear ESS community, from a clinical point of view, I found the JAMA publication with the results of the ADAPT-Sepsis trial by Dark *et al.* very interesting.

<b>JAMA</b> <sup>®</sup>	JAMA. 2025;333(8):682-693. doi:10.1001/jama.2024.26458
<b>Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis</b>	
<b>The ADAPT-Sepsis Randomized Clinical Trial</b>	
<small>Paul Dark, MD, PhD<sup>1</sup>; Anower Hossain, PhD<sup>2</sup>; Daniel F. McAuley, MD<sup>3,11</sup>; David Brealey, MD<sup>4</sup>; Gordon Carlson, MD<sup>5</sup>; Jonathan C. Clayton, MPhil, MSc<sup>6</sup>; Timothy W. Felton, PhD, MD<sup>7</sup>; Belinder K. Ghuman, BSc<sup>2</sup>; Anthony C. Gordon, MBBS, MD<sup>8</sup>; Thomas P. Hellyer, MD<sup>9,16</sup>; Nazir I. Lone, MD<sup>10</sup>; Uzma Manazar, MSc<sup>2</sup>; Gillian Richards<sup>2</sup>; Iain J. McCullagh, MD<sup>9</sup>; Ronan McMullan, MD<sup>3,11</sup>; James J. McNamee, MD<sup>11</sup>; Hannah C. McNeil, BSc<sup>2</sup>; Paul R. Mouncey, MSc<sup>12</sup>; Micheal J. Naisbitt, MD<sup>13</sup>; Robert J. Parker, MD<sup>14</sup>; Ruth L. Poole, MPhil<sup>15</sup>; Anthony J. Rostron, PhD<sup>16,17</sup>; Mervyn Singer, MD<sup>18</sup>; Matt D. Stevenson, PhD<sup>19</sup>; Tim S. Walsh, MD<sup>10</sup>; Ingeborg D. Welters, MD<sup>20</sup>; Tony Whitehouse, MD<sup>21</sup>; Simon Whiteley, MD<sup>22</sup>; Peter Wilson, MD<sup>23</sup>; Keith K. Young<sup>2</sup>; Gavin D. Perkins, DSc<sup>2</sup>; Ranjit Lall, PhD<sup>2</sup>; for the ADAPT-Sepsis Collaborators</small>	


The study looked at an old question again: How useful are biomarkers like PCT and CRP when it comes to antibiotic use in sepsis? After six years of recruiting patients, the study showed what we know from our guidelines—PCT-guided therapy reduces antibiotic use by about one day compared to standard treatment (significant). When such a large study, with over 16,000 patients screened, does not bring many new findings, it makes you wonder. It seems many clinicians still believe that inflammation-guided therapy can make a difference, but are we using the right markers? The upcoming RISC-trial builds on this published data and, for the first time, includes new cellular markers. We are excited to see what comes out of it!

- Large randomized controlled trial (RCT)
- Clear protocol
- Even with a large group, the difference in antibiotic use—PCT vs. standard—is small, but still significant (9.8 vs. 10.7 days).
- Are PCT and CRP really the right markers for the patient's clinical condition?


Martin Sebastian Winkler  
(ESS Member)

# Spotlighting the Most Important Publication You Read in 2024/25 – Part 2


DOI: [10.1038/s41590-023-01722-8](https://doi.org/10.1038/s41590-023-01722-8)



nature immunology | Vol. 25 | Feb. 2024 | 226–239  
**A pairwise cytokine code explains the organism-wide response to sepsis**  
 Michihiro Takahama ... Nicolas Chevrier



In this study, the authors map dynamic gene expression changes across multiple organs during sepsis and compare these patterns to the effects of six individual and fifteen pairwise recombinant cytokine treatments. Remarkably, combinations of TNF with IL-18, IL-1 $\beta$ , or IFN $\gamma$  closely recapitulate the transcriptional and tissue-level responses observed in murine CLP or LPS sepsis models. To uncover the cellular underpinnings of these effects, the team quantified shifts in the abundance of 195 cell types across nine organs, validated through whole-body spatial profiling. This work distills the complex cytokine storm of sepsis into a coherent pairwise cytokine code, offering new insight into the coordinated gene, cell, and organ-level responses driving disease progression.




DOI: [10.1111/jcmm.17938](https://doi.org/10.1111/jcmm.17938)

The authors investigated the transcriptomic of six tissues—colon, brain, heart, kidney, and lung—from patients who died of sepsis. Their analysis beautifully illustrates the concept of compartmentalization: while septic shock is highly heterogenous across individuals and tissues, several pathways—such as respiratory electron transport and metabolic functions—showed distinctive, tissue-specific alterations. The lungs and colon were among the most affected, and strikingly, the study also identified transcriptome signatures of accelerated aging in sepsis patients.

J Cell Mol Med. 2023; 27: 3157–3167

## Transcriptome analysis of six tissues obtained post-mortem from sepsis patients

Fabiano Pinheiro da Silv, André Nicolau Aquime Gonçalves, Amaro Nunes Duarte- Neto, Thomaz Lüscher Dias, Hermes Vieira Barbeiro, Cristiane Naffah Souza Breda, Leandro Carvalho Dantas Breda, Niels Olsen Saraiva Câmara, Helder I. Nakaya



[Back to Contents](#)

DOI: [10.1101/2023.01.30.526342](https://doi.org/10.1101/2023.01.30.526342)


**bioRxiv**  
THE PREPRINT SERVER FOR BIOLOGY

2023 Feb 2:2023.01.30.526342

## Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation

Michihiro Takahama, Ashwini Patil, Katherine Johnson, Denis Cipurko, Yoshimi Miki, Yoshitaka Taketomi, Peter Carbonetto, Madison Plaster, Gabriella Richey, Surya Pandey, Katerina Cheronis, Tatsuki Ueda, Adam Gruenbaum, Steven M Dudek, Matthew Stephens, Makoto Murakami, Nicolas Chevrier

In this yet-to-be-published study, the authors identify phospholipase A2 Group V (PLA2G5) as a previously unrecognized key player of sepsis. They



show that PLA2G5 is specifically upregulated in the murine gut following LPS or CLP challenge. Mice lacking PLA2G5 are resistant to lethal LPS injection, and treatment with anti-PLA2G5 antibodies protects the LPS-injected wild-type mice. Mechanistically, circulating PLA2G5 induces intravascular hemolysis via its lipolytic activity on red blood cell

membranes. In human sepsis—whether bacterial, viral, or fungal sepsis—plasma levels of PLA2G5 are elevated and correlate with disease severity, suggesting that sepsis hijacks this enzyme, transforming it into a systemic self-venom that targets red blood cells.


DOI: [10.1016/S0140-6736\(24\)01867-1](https://doi.org/10.1016/S0140-6736(24)01867-1)

A standout figure in this global review of antimicrobial resistance (AMR) from 1990 to 2021 charts sepsis-related deaths by age group, revealing a compelling trend: mortality in children under 4 has significantly declined, while rates among adults and older individuals have remained steady. Notably, peaks in 2020 and 2021 correspond to surges in SARS-CoV-2-related viral sepsis, highlighting how emerging infections continue to shape the landscape of AMR.

**THE LANCET** 2024 Sep 28;404(10459):1199-1226

## Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050


GBD 2021 Antimicrobial Resistance Collaborators



[Back to Contents](#)

DOI: [10.1186/s10020-024-01052-x](https://doi.org/10.1186/s10020-024-01052-x)

Molecular Medicine 2024; 30: 280

**Molecular profiles of blood from numerous species that differ in sensitivity to acute inflammation**David J. Gregory<sup>1,2†</sup>, Feifei Han<sup>2,3†</sup>, Peng Li<sup>2,3</sup>, Marina A. Gritsenko<sup>4</sup>, Jennifer Kyle<sup>4</sup>, Frank E. Riley<sup>1</sup>, Deborah Chavez<sup>5</sup>, Vania Yotova<sup>6</sup>, Renata H. M. Sindeaux<sup>6</sup>, Mohamed B. F. Hawash<sup>6,7,15</sup>, Fengyun Xu<sup>8</sup>, Li-Yuan Hung<sup>3</sup>, Douglas L. Hayden<sup>2,3^</sup>, Ronald G. Tompkins<sup>2,3^</sup>, Robert E. Lanford<sup>5^</sup>, Lester Kobzik<sup>9</sup>, Judith Hellman<sup>8</sup>, Jon M. Jacobs<sup>4</sup>, Luis B. Barreiro<sup>6,7,10,11,12,13</sup>, Wenzhong Xiao<sup>2,3\*</sup> and H. Shaw Warren<sup>1</sup>

lipidomes of six LPS-sensitive species (rabbit, pig, sheep, cow, chimpanzee, human) and four LPS-resilient species (mice, rats, and baboon), both at rest and after exposure to LPS. Surprisingly, sensitive species already showed elevated expression of LPS-responsive genes at baseline. Following LPS stimulation, resilient species upregulated genes involved in LPS detoxification, bacterial growth suppression, autophagy, apoptosis, and discrimination between sepsis from SIRS inflammation. The findings reveal a molecular roadmap for species-specific inflammatory responses and may guide the development of


better preclinical models and targeted therapies that limit inflammation without comprising immunity.

DOI: [10.1016/j.chom.2024.08.007](https://doi.org/10.1016/j.chom.2024.08.007)

A recent study shed light on the paradoxical role of TNF in sepsis, revealing that its lethal effects are mediated through Paneth cells. In an elegant set of experiments, the authors demonstrated that TNF-induced lethality is abolished in mice lacking the TNF receptor P55 in Paneth cells. Mechanistically, TNF triggers an interferon response and suppresses the steady-state unfolded protein response in these cells by downregulating key UPR genes, *Ern1* and *Ern2*. This UPR deficiency impairs antimicrobial peptide production and diminishes Paneth cell-mediated defense, leading to bacterial translocation, polymicrobial sepsis, organ failure, and death. These findings highlight Paneth cells as central players in bacterial control and potential targets for sepsis therapy.

Cell Host &amp; Microbe

2024 Oct 9;32(10):1725-1743.e7.

**Paneth cell TNF signaling induces gut bacterial translocation and sepsis**Charlotte Wallaey<sup>1,2,13</sup>, Natalia Garcia-Gonzalez<sup>1,2,13</sup>, Steven Timmermans<sup>1,2</sup>, Jolien Vandewalle<sup>1,2</sup>, Tineke Vanderhaeghen<sup>1,2</sup>, Somara De Beul<sup>1,2</sup>, Hester Dufoor<sup>1,2</sup>, Melanie Eggermont<sup>1,2</sup>, Eise Moens<sup>1,2</sup>, Victor Bosteels<sup>1,3,4</sup>, Riet De Rycke<sup>2,5</sup>, Fabien Thery<sup>6,7</sup>, Francis Impens<sup>3,7,8</sup>, Serge Verbanck<sup>9</sup>, Stefan Lienenklauss<sup>9</sup>, Sophie Janssens<sup>1,3,4</sup>, Richard S. Blumberg<sup>11</sup>, Takao Iwawaki<sup>12</sup> and Claude Libert<sup>1,2,14,\*</sup>Jean-Marc Cavaillon  
(Past President and ESS Member)[Back to Contents](#)

## New S3 Guideline on Intensive Care Medicine After Polytrauma Published

On August 1, 2024, the first S3 guideline on the intensive care management following polytrauma, led by the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI) was published by the AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.; Association of the Scientific Medical Societies in Germany). The guideline addresses the urgent need for structured recommendations beyond the initial acute care phase of adult polytrauma patients.

Coordinated by Prof. Gernot Marx (Department of Intensive Care and Intermediate Care, University Hospital Aachen) and Prof. Frank Hildebrand (Department of Trauma and Reconstructive Surgery, University Hospital Aachen), the guideline provides evidence-based and consensus-driven recommendations for the highly complex care of severely injured patients—such as those involved in major accidents or affected by war-related trauma.

The comprehensive document includes five evidence-based and numerous consensus-based recommendations developed by a panel of more than 50 experts from 25 medical societies. Among other key topics, it offers guidance on the optimal timing for surgical interventions, and emphasizes the importance of interdisciplinary communication and team-based decision-making.

The guideline also highlights a significant gap in high-quality clinical research focused specifically on polytrauma patients, underscoring the need for further studies in this field. This new S3 guideline marks an important step toward standardized, high-quality intensive care for polytrauma patients across Germany.

*Reference: German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI): S3 Guideline on Intensive Care after Polytrauma (AWMF Registry No. 040-014), Version 1.0 (July 24, 2024). <https://register.awmf.org/de/leitlinien/detail/040-014>*

Nils Becker  
(ESS Member)

## **New European White Book on Polytrauma Management across Europe by the European Society for Trauma and Emergency Surgery (ESTES) published**

The recently published European White Book on Polytrauma Management, initiated by the Polytrauma Section of the European Society for Trauma and Emergency Surgery (ESTES), presents a comprehensive, evidence-based framework for harmonizing trauma care across Europe. Trauma continues to pose a significant socioeconomic burden and remains a leading public health challenge throughout the continent. However, treatment strategies, clinical pathways, and organizational structures still vary widely between European countries.

The newly released consensus document aims to define key principles and establish minimum standards for the care of highly vulnerable polytrauma patients. Covering the entire continuum of trauma care—from pre-hospital management and emergency treatment to definitive care and rehabilitation—the White Book outlines essential requirements for infrastructure, staffing, training, and quality assurance.

Designed to be adaptable to the diversity of healthcare systems across Europe, the White Book seeks to reduce inconsistencies in care, improve patient outcomes, and support national and regional initiatives in building resilient, high-performing trauma care networks.

This authoritative reference serves as a crucial guide for clinicians, healthcare administrators, policymakers, and system planners who are committed to improving trauma care delivery and outcomes throughout Europe.

*Reference: Pfeifer, R., Hildebrand, F., Gaarder, C. et al. European white book on polytrauma management – setting standards for trauma care across Europe. Eur J Trauma Emerg Surg 51, 170 (2025). <https://doi.org/10.1007/s00068-025-02834-6>*

Nils Becker  
(ESS Member)

## The Global Sepsis Alliance Amplifies Advocacy and Partnership Efforts

The Global Sepsis Alliance (GSA) made remarkable progress in positioning Sepsis higher in the political and global health dialogue. This progress included the high-profile launch of the 2030 Global Agenda for Sepsis and statements at the 77th Session of the World Health Assembly and the UN High Level Meeting on AMR, the creation of the Global Sepsis Innovation Platform, and the Caribbean Sepsis and AMR Alliance.

In early 2025, the GSA and Sepsis Stiftung had the honor of hosting the renowned American Actor and Filmmaker Bill Pullman in Berlin, contributing to the filming of a documentary on AMR and Sepsis, and elevating Sepsis advocacy to a new level.

### Launch of the 2030 Global Agenda for Sepsis

The GSA led the development of the 2030 Global Agenda for Sepsis, the first multi-year global strategy, with the engagement of 6 Regional Sepsis Alliances, and over 70 member and partner organizations from Africa, Asia-Pacific, the Caribbean, Eastern Mediterranean, Europe, Latin America, and North America.

The document was launched at the German Bundestag under the leadership of Prof. Dr. Andrew Ullmann, Chair of the Global Health Sub-Committee, and Dr. Mariam Jashi – CEO of the Global Sepsis Alliance and former member of Parliament of Georgia. The event was convened in partnership with the UNITE Parliamentarians Network for Global Health and the Virchow Foundation. Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, emphasized the importance of the 2030 Global Agenda and the leadership of the Global Sepsis Alliance in a special video message.

This first global strategy calls for concerted effort by UN Member States and multiple stakeholders to tackle the significant human, societal, healthcare, and economic burden of Sepsis through political leadership and multilateralism, health system readiness for Sepsis and its sequelae, whole-of-society response, Sepsis research and innovations, and integration into pandemic and emergency preparedness plans. More information:

<https://globalsepsisalliance.org/2030-global-agenda-for-sepsis>

### The Global Sepsis Innovations Platform

In February 2025, the GSA, in collaboration with Sepsis Stiftung, launched the Global Sepsis Innovations Platform (GSIP) to foster coordinated discussions and advocacy in the following areas:

- **Knowledge Exchange:** Facilitating collaboration among innovators, researchers, healthcare professionals, sepsis survivors, and patients' families.
- **Regulatory Collaboration:** Engaging in consensus-building discussions and formulating recommendations and position statements for sepsis innovation authorization.
- **Advocacy Coordination:** Working with governments, foundations, industry, and research institutions to increase investments in sepsis research and development.
- **Operational Research Coordination:** Addressing accessibility and affordability of sepsis-related equipment and supplies, especially in low- and middle-income countries.
- **Defining Sepsis R&D Agenda:** Identifying critical research priorities, especially for low- and middle-income countries, including vaccines, early detection and treatment strategies, and AI solutions.

The first 36 members of the platform from 21 countries represent academic institutions, healthcare providers, civil society organizations, and industry partners. Prof. Niranjana ‘Tex’ Kisson – GSA President and Prof. Konrad Reinhart – President of Sepsis Stiftung Co-chair the GSIP. Prof. Evangelos J. Giamarellos-Bourboulis, Chair of the European Sepsis Alliance (ESA) and the former President of the European Shock Society (ESS), leads the Sepsis Treatment and Care working group. More information:

<https://www.worldsepsisday.org/news/2025/3/12/inaugural-meeting-of-global-sepsis-innovations-platform-gsip>

### 5<sup>th</sup> World Sepsis Congress

The annual flagship event of the Global Sepsis Alliance, held on April 8–9, welcomed over **11,900 participants from around the world**. The 5<sup>th</sup> World Sepsis Congress on "Sepsis Research and Innovations" provided a platform for over 100 international experts to discuss advancements in Sepsis prevention, diagnosis, treatment, and post-Sepsis care.

The Congress featured special addresses and interventions from Dr. Tedros Ghebreyesus - WHO Director-General, Hon. Craig Mackinlay – Member of the House of Lords, H.E. Frank Anthony – Health Minister of Guyana, Sir Jeremy Farrar – WHO Chief Scientist, Hon. Ricardo Baptista Leite – UNITE President, and other prominent political and global health leaders.

13 Scientific Sessions and the panel of Sepsis Survivors and families affected by this devastating emergency, explored cutting-edge knowledge and research on prevention through immunization and IPC, early detection through diagnostics and AI-driven solutions, novel therapeutics, as well as the interconnection of Sepsis with AMR, pandemic preparedness, climate change, and other emergencies, illustrating how interconnected global health challenges can shape the future Sepsis responses. Special sessions were dedicated to the role of healthcare systems in enhancing Sepsis prevention and post-Sepsis recovery, with a focus on improving Sepsis care pathways across resource-limited settings. More information:

<https://www.worldsepsiscongress.org/>

### Sepsis Dialogue in the EU Parliament

The 8<sup>th</sup> Annual Meeting of the European Sepsis Alliance (ESA), held on March 19 in the European Parliament, focused on embedding Sepsis strategies into EU health security and resilience plans. With the patronage of MEP Vytenis Andriukaitis, former European Commissioner for Health and Food Safety, the meeting emphasized the urgency of integrating Sepsis into EU policies. ESA and GSA presented a Call to Action, “**Stop Sepsis – the leading cause of preventable deaths and disability in Europe,**” endorsed by 15 European and global health organizations. More information:

<https://www.europeansepsisalliance.org/news/2025/3/31/8th-esa-annual-meeting-report-putting-patients-education-and-awareness-at-the-centre-of-a-european-sepsis-plan>

### Outlook for 2025 World Sepsis Day

On September 13, the 2025 World Sepsis Day (WSD) will renew emphasis on global media outreach and public awareness. Building on previous campaigns, the GSA plans to launch an extensive media-oriented campaign aimed at raising Sepsis literacy among the public, healthcare professionals, and politicians. Press conferences will be organized in Geneva and Berlin, featuring key global health organizations, policymakers, and Sepsis survivors. Additionally, regional and national media events across the GSA’s network will promote the goals of the 2030 Global Agenda for Sepsis, highlight the need for urgent action, and further solidify Sepsis as a global health priority.

Mariam Jashi  
CEO of the Global Sepsis Alliance

## Welcome New ESS Members

WELCOME

**Christian Bergmann**

Ulm, Germany

**Marcela Hortova-**

**Kohoutkova**

Brno, Czech Republic

**Vicent Ribas-Ripoll**

Catalunya, Spain

**Rebecca Halbgebauer**

Ulm, Germany

**Jan Fric**

Brno, Czech Republic

**Carsten P. Marcus**

Düsseldorf, Germany

**Martin Sebastian  
Winkler**

Göttingen, Germany

**Nico Sollmann**

Ulm, Germany

**Malick Paye**

Lyon, France

**Jasmin M. Bülow**

Ulm, Germany

**Birte Weber**

Frankfurt, Germany

**Nils Becker**

Ulm, Germany

**Helen Rinderknecht**

Ulm, Germany

## Upcoming Events



**The Society for Cardiovascular Angiography and Interventions (SCAI)**  
May 1-3, 2025, Washington D.C.  
<https://scai.org/scai-2025-scientific-sessions>

**2025**  
Washington,  
D.C. MAY 1-3



**European Congress on Surgical Infections (SIS-E)**  
May 14-16, 2025, Dublin Ireland  
<https://sis-e.org/2025/>



14 - 16 MAY 2025 | RCSI, DUBLIN, IRELAND



**9th E.S.T.R.O.T. CONGRESS**  
**European Society of Tissue Regeneration in Orthopedics and Traumatology**  
May 30-June 1, 2025, Leeds, UK  
<https://www.estrot.org>



**48th Annual Conference on Shock**  
May 31-June 3, 2025, Boston MA  
<https://www.shocksociety.org/annual-conference-of-shock-2025>



The European Society  
for Organ Transplantation

**ESOT Congress 2025**  
June 29-July 2, 2025,  
London, UK  
<https://esot.org/>



**ISICEM 2026 – 45th International Symposium on Intensive Care and Emergency Medicine**  
March 17-20, 2026, Brussels, Belgium  
<https://www.isicem.org/1/Home.asp>



**2026 Critical Care Congress**  
March 22-24, 2026,  
Chicago, IL  
<https://www.sccm.org/Annual-Congress/critical-care-conference>



**25th European Congress of Trauma & Emergency Surgery (ECTES)**  
May 17-19, 2026, Kistamässan, Stockholm, Sweden  
<https://www.estes-congress.org/>



**39th Annual Congress of the European Society of Intensive Care Medicine**  
October 10-14, 2026, Lisbon, Portugal  
<https://www.esicm.org/events/39th-annual-congress-lisbon/>



Andrea Szabó

[Back to Contents](#)

## Invitation to Publish in *Shock*®



*Shock* is a peer-reviewed monthly journal dedicated to publishing high-quality research in the fields of injury, inflammation, and sepsis—covering both clinical and experimental studies. With a current Impact Factor of 2.7, *Shock* serves as the official Journal of all international Shock Societies, including the European Shock Society.

Thanks to its efficient peer-review process, authors typically receive an initial decision within 15 days of submission.

We warmly encourage you to consider *Shock* for your next impactful manuscript!

<http://www.editorialmanager.com/shock>.

## "A new/old course for the *Shock* journal" or "A new vision for *Shock*"

*Shock* encourages submissions of high-quality manuscripts to the journal. We offer a rapid turnaround time for the initial peer review, with an average of fewer than 14 days. To increase visibility and reach, *Shock* now actively promotes published articles on social media platforms including Bluesky, X and LinkedIn. You can find these papers by searching #Shockjournal.

At the 2025 US Shock Conference, four authors were invited to present their work based on the number of times their paper was downloaded from *Shock*. Among them was Dr. Ieni Xourgia, M.D., MSc, from the University Clinic for Emergency Medicine, Inselspital, University of Bern, Bern, Switzerland, Acetate Ringer's Solution Versus Normal Saline Solution In Sepsis: A Randomized, Controlled, Trial.

Daniel Remick  
*Shock* Editor-in-Chief

## The Executive Committee of ESS



### The President:



Borna Relja, PhD  
 Head of Translational and Experimental Trauma Research  
 Department of Trauma, Hand, Plastic and Reconstructive Surgery  
 University Clinic Ulm, Ulm University  
 Albert-Einstein-Allee 23  
 D-89081 Ulm  
 Phone: +49 731/500-54567  
 e-mail: [info@bornarelja.com](mailto:info@bornarelja.com)

### The President-Elect:



Marc Maegele, MD, PhD  
 Department of Trauma and Orthopedic Surgery  
 Institute for Research in Operative Medicine (IFOM)  
 Cologne-Merheim Medical Center (CMMC), University of  
 Witten/Herdecke  
 Ostmerheimer Str. 200  
 51109 Cologne, Germany  
 Phone: +49 221/8907-13614  
 e-mail: [Marc.Maegele@t-online.de](mailto:Marc.Maegele@t-online.de)

### The Past-President:



Marcin F. Osuchowski, DVM, PhD  
 Ludwig Boltzmann Institute for Experimental and Clinical Traumatology  
 Donaueschingenstrasse 13  
 1200 Vienna, Austria  
 Phone: +43-1-33110 469  
 e-mail: [marcin.osuchowski@trauma.lbg.ac.at](mailto:marcin.osuchowski@trauma.lbg.ac.at)

**The General Secretary:**

Andrea Szabó MD, PhD  
 Institute of Surgical Research  
 University of Szeged  
 Szókefalvi-Nagy B. 1.  
 H-6720 Szeged, Hungary  
 Phone: +36 62 545 106  
 e-mail: [szabo.andrea.exp@med.u-szeged.hu](mailto:szabo.andrea.exp@med.u-szeged.hu)

**The Treasurer:**

Sina M. Coldewey, MD, PhD  
 Institute of Anaesthesiology Perioperative Medicine  
 University Hospital Zurich  
 Rämistrasse 10  
 CH-8091 Zurich, Switzerland  
 Phone: +41 44 255 26 96  
 e-mail: [sina.coldewey@uzh.ch](mailto:sina.coldewey@uzh.ch)

**The Elected Councillors:**


Stefanie Flohé, PhD  
 Essen University Hospital  
 Research Group Immunology Sepsis/Trauma  
 Department of Trauma, Hand, and Reconstruction Surgery  
 Hufelandstr. 55  
 45147 Essen, Germany  
 Phone: +49 201/723-4405  
 e-mail: [stefanie.flohe@uk-essen.de](mailto:stefanie.flohe@uk-essen.de)



Tomasz Skirecki, MD, PhD



Federico Aletti, PhD  
Institute of Science and Technology (ICT)  
Universidade Federal de São Paulo (UNIFESP)  
Rua Talim, 330 - São José dos Campos, SP  
Brazil  
CEP 12231-280  
e-mail: [faletti@unifesp.br](mailto:faletti@unifesp.br)



Markus Huber-Lang, MD  
Professor and Chair  
Institute for Clinical and Experimental Trauma-Immunology  
University Hospital of Ulm  
Helmholtzstr. 8/1  
89081 Ulm, Germany  
Phone +49-731-500-54801  
e-mail: [markus.huber-lang@uniklinik-ulm.de](mailto:markus.huber-lang@uniklinik-ulm.de)



Brendon P. Scicluna, PhD  
Senior Lecturer and Principal Investigator  
Department of Applied Biomedical Science  
Faculty of Health Sciences  
University of Malta  
Msida, Malta  
Phone: +356 23403869  
e-mail: [brendon.scicluna@um.edu.mt](mailto:brendon.scicluna@um.edu.mt)

**Councillors appointed by the President:**

Rebecca Halbgebauer, PhD  
 Institute of Clinical and Experimental Trauma Immunology  
 Ulm University Medical Center  
 Helmholtzstr. 8/1  
 D-89081 Ulm  
 Phone: +49 731 50054806  
 e-mail: [rebecca.halbgebauer@uniklinik-ulm.de](mailto:rebecca.halbgebauer@uniklinik-ulm.de)



Christian Bergmann, MD  
 Translational and Experimental Trauma Research  
 Department of Trauma, Hand, Plastic and Reconstructive Surgery  
 University Clinic Ulm, Ulm University  
 Albert-Einstein-Allee 23  
 D-89081 Ulm  
 Phone: +49 731/500-0  
 e-mail: [christian.bergmann@uniklinik-ulm.de](mailto:christian.bergmann@uniklinik-ulm.de)

**The Auditors:**

Antigoni Kotsaki, MD, PhD  
 4th Department of Internal Medicine  
 ATTIKON University Hospital  
 1 Rimini Str  
 12462 Athens, Greece  
 Phone: +30 694 663 7164  
 e-mail: [antigonebut@yahoo.com](mailto:antigonebut@yahoo.com)



Anna Herminghaus, MD, DESA  
 Department of Anesthesiology,  
 Duesseldorf University Hospital  
 Moorenstr. 5  
 40225 Düsseldorf  
 Phone: +49 211 81 05102  
 e-mail: [anna.herminghaus@med.uni-duesseldorf.de](mailto:anna.herminghaus@med.uni-duesseldorf.de)

**The Editor-in-Chief of SHOCK®:**

Daniel G. Remick, MD  
 Department of Pathology and Laboratory Medicine, Boston University School  
 of Medicine and Boston Medical Center,  
 670 Albany St Biosquare III, Boston, MA, USA  
 Phone: 001 617 414 7043  
 e-mail: [remickd@bu.edu](mailto:remickd@bu.edu)

## ESS Membership

Dear ESS members,

please kindly pay your ESS membership for 2025-2027.

Currently, a fixed 2-year membership fee of EUR 100 for regular members and EUR 50 for student members applies.

We sincerely appreciate your contribution; please do not ignore this important commitment.

Dear new and old ESS Members, you can renew your membership also here:

<https://europeanshocksociety.org/ESS-Membership>

Please kindly pay your 2-year ESS membership via Stripe or transfer.

*2 Year Membership Payments via Stripe (credit card, Klarna, eps-transfer, Bancontact, iDEAL):*

Stripe for full membership: <https://buy.stripe.com/14kcOYgDo75bdsAfYZ>

Stripe for student membership: <https://buy.stripe.com/aEU5mw2MycpviewE002>

*2 Year Membership Payments via transfer:*

European Shock Society

IBAN: AT13 1420 0200 1093 6552

BIC: BAWAATWW

Easybank

*Please identify your transfer with your first/last name and a "full/student ESS membership fee" annotation.*

Thank you!

## How to Become an ESS Member?

Those who are willing to join ESS as new members, please submit an [ESS membership application form](https://europeanshocksociety.org/researchDbForm): <https://europeanshocksociety.org/researchDbForm>

The process also includes confirmation of your e-mail address.

After receiving a feedback from us (via e-mail), the next step is payment of the membership fee (see above). Receipt of your payment will be also sent by e-mail.

[Advantages of being a member of ESS: https://europeanshocksociety.org/home](https://europeanshocksociety.org/home)

## Last Words About the ESS Newsletter



### Dear Current ESS Member,

If you've enjoyed our ESS Spring Newsletter, we warmly encourage you to share it with your colleagues across your lab, department or institute. This could also be a great opportunity to invite them to join our community—registration details can be found at the end of this Newsletter.

Remember, your active involvement is vital for the continued growth and strength of our society. Together, we can ensure that the ESS remains a proud and leading voice among other international Shock Societies.

This Newsletter, curated by fellow members, is your platform. We invite you to connect with it, contribute to it, and help shape its future. We would be thrilled to feature your input in upcoming issues—whether it's a research perspective, popular science commentary, job posting, journal club contributions, historical reflections, or insights on diverse topics like Sepsis 3.0, AI etc.

### Dear Former ESS Member,

We kindly remind you to renew your membership. The ESS relies on the engagement of both junior and senior colleagues to continue representing the best of European shock research—at the bedside and the bench. Your presence is valued, and your support is essential to our shared mission.



*ESS acronym explanation by Mouna Ben Azaiz; Crossword by Andrea Szabó*

Your ESS Executive Committee and Your President Borna Relja

[Back to Contents](#)